Aberdeen Group plc Trims Stock Position in ANI Pharmaceuticals, Inc. $ANIP
Aberdeen Group plc reduced its stake in ANI Pharmaceuticals (NASDAQ:ANIP) by 26.3% in the third quarter, selling 96,255 shares and ending with 269,678 shares valued at approximately $24.7 million. Institutional investors collectively hold about 76.05% of the stock, while company insiders have recently been net sellers, divesting 4,322 shares worth $354,816 in the last three months. Analyst sentiment remains mixed-to-positive, with a consensus "Moderate Buy" rating and an average price target of $103.43.
Ani Pharmaceuticals SVP Cook sells $38,400 in stock By Investing.com
Meredith Cook, SVP at ANI Pharmaceuticals (NASDAQ:ANIP), sold 500 shares for $38,400 on February 13, 2026, and disposed of additional shares for tax purposes on February 12 and 14. Following these transactions, Cook directly owns 67,550 shares. The company reports strong financial health, with analysts maintaining a bullish consensus ahead of earnings on February 27, and projects over $1 billion in revenue for 2026.
Ani Pharmaceuticals SVP Cook sells $38,400 in stock
Meredith Cook, SVP at ANI Pharmaceuticals (NASDAQ:ANIP), sold 500 shares of common stock for $38,400 on February 13, 2026. This transaction was part of a Rule 10b5-1 trading plan. Cook also disposed of shares on February 12 and 14 for tax purposes related to restricted stock vesting, and she directly owns 67,550 shares post-transactions.
ANI Pharmaceuticals to Release 2025 Financial Results
ANI Pharmaceuticals (ANIP) announced it will release its Q4 and full-year 2025 financial results on February 27, 2026, before market open, followed by an 8:00 AM ET conference call with CEO Nikhil Lalwani and other executives. A webcast of the event will be available on the company's website. The company specializes in developing and commercializing therapeutics across various medical fields, focusing on the rare disease market.
Tax-withholding share disposition by ANI Pharmaceuticals (ANIP) executive
Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals (ANIP), reported a tax-withholding disposition of 4,546 shares of company common stock on February 11, 2026, at $76.25 per share. This transaction was related to the vesting of 11,578 performance stock units granted earlier and was exempt under Rule 16(b)-3. Following the withholding, Mutz directly holds 102,771 shares of ANI Pharmaceuticals.
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before the market opens. Company executives, including President and CEO Nikhil Lalwani, will host a conference call at 8:00 a.m. ET to discuss these results. The call details and webcast information for live and archived access are provided.
ANI Pharmaceuticals to Release 2025 Financial Results
ANI Pharmaceuticals has announced it will release its fourth quarter and full-year 2025 financial results on February 27, 2026, before market open. CEO Nikhil Lalwani and other executives will host a conference call at 8:00 AM ET on the same day. The company focuses on developing and commercializing innovative therapeutics in various fields, demonstrating sustained growth potential in the rare disease market.
ANI Pharmaceuticals, Inc. to Release Q4 and Full Year 2025 Financial Results on February 27, 2026
ANI Pharmaceuticals, Inc. will release its Q4 and full-year 2025 financial results on February 27, 2026, before market open, followed by a conference call with CEO Nikhil Lalwani, CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. The call will discuss the company's performance and be accessible via a toll-free number or webcast on their website. The company is a diversified biopharmaceutical firm focusing on rare diseases, generics, and branded pharmaceuticals.
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced it will release its fourth quarter and full year 2025 financial results on February 27, 2026, before market open. A conference call will be held on the same day at 8:00 a.m. ET with company executives to discuss the results. Investors can access the webcast live or on replay via the company's website.
Thrivent Financial for Lutherans Has $5.32 Million Stake in ANI Pharmaceuticals, Inc. $ANIP
Thrivent Financial for Lutherans significantly increased its stake in ANI Pharmaceuticals (NASDAQ: ANIP) by 363.8% during Q3, now holding 58,027 shares valued at $5.32 million. Analysts generally view ANIP positively, with a "Moderate Buy" consensus and an average price target of $103.43. The specialty pharmaceutical company recently reported strong quarterly earnings, surpassing expectations with an EPS of $2.04 and revenue of $227.8 million.
Ranger Investment Management L.P. Decreases Stock Position in ANI Pharmaceuticals, Inc. $ANIP
Ranger Investment Management L.P. significantly decreased its holdings in ANI Pharmaceuticals by 49.2% in the third quarter, selling 262,888 shares and retaining 271,345 shares valued at $24.86 million. Despite this reduction, ANI Pharmaceuticals delivered strong financial results, surpassing earnings and revenue expectations, which led to positive analyst sentiment and upward revisions to price targets. The company currently holds a "Moderate Buy" consensus rating from analysts, with various institutional investors also adjusting their positions in the stock.
Is ANI Pharmaceuticals (ANIP) Pricing Reflect Long Term Cash Flow Potential?
This article analyzes ANI Pharmaceuticals' (ANIP) valuation using two methods: Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio. The DCF analysis suggests ANIP is significantly undervalued at $369.24 per share compared to its current price of $81.27, implying an intrinsic discount of 78.0%. However, the P/E ratio of 49.75x indicates that the stock is overvalued when compared to the industry average and Simply Wall St's proprietary Fair Ratio of 21.42x.
ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis: A Promising 37.97% Upside Awaits Investors
ANI Pharmaceuticals, Inc. (ANIP) is presented as an intriguing investment opportunity in the drug manufacturing sector, with a current stock price of $80 and an impressive 37.97% potential upside to an average target price of $110.38. The company boasts robust financials, including 53.60% revenue growth, an EPS of $1.60, and over $116 million in free cash flow. Analyst sentiment is highly positive, with seven buy ratings and no sell ratings, reinforcing its potential as a growth stock.
Did 53.60% Revenue Growth and Portfolio Expansion Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?
ANI Pharmaceuticals recently reported significant revenue growth of 53.60% and is expanding its product portfolio, attracting strong analyst and investor interest with seven buy ratings. While this growth strengthens its investment narrative, the stock trades at a high earnings multiple with some past profits from one-off gains and tight interest coverage. Investors should consider that current profitability has one-off support and the share price might still be above fair value, despite recent softness.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of "Moderate Buy" by Brokerages
Nine analysts have given ANI Pharmaceuticals (NASDAQ:ANIP) a "Moderate Buy" rating, with an average 12-month price target of $103.43. The company recently reported strong quarterly earnings, beating consensus estimates with $2.04 EPS and $227.81 million in revenue, representing a 53.6% year-over-year increase. Insider activity includes sales of 28,101 shares in the past 90 days, while institutional investors hold 76.05% of the stock.
ANI Pharmaceuticals, Inc. $ANIP is Lisanti Capital Growth LLC's 5th Largest Position
Lisanti Capital Growth LLC reduced its stake in ANI Pharmaceuticals (ANIP) by 13.3%, yet the stock remains its 5th largest holding, valued at $7.56 million, with institutions owning 76.05%. Company insiders have been net sellers, with significant share sales by a VP and SVP totaling about $2.45 million in 90 days. Despite insider sales, ANI Pharmaceuticals reported a strong earnings beat and positive FY2025 guidance, with analysts giving a consensus "Moderate Buy" rating and an average target price of $103.43.
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
Implied volatility for ANI Pharmaceuticals (ANIP) stock options is surging, particularly for the Apr 17, 2026 $55.00 Call, indicating that the market anticipates a significant price movement. Despite this, analysts have slightly revised earnings estimates downwards, though the stock holds a Zacks Rank #2 (Buy). This situation suggests a potential options trading opportunity, especially for strategies involving selling premium.
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Passes Below Fifty Day Moving Average - Here's What Happened
ANI Pharmaceuticals (NASDAQ:ANIP) stock recently fell below its 50-day moving average of $81.82, trading as low as $81.11, despite beating quarterly earnings and revenue expectations with 53.6% year-over-year growth. Analysts generally rate the stock a "Moderate Buy" with an average target price of $103.43, and institutional investors have significantly increased their holdings. However, company insiders have sold over 28,000 shares in the last 90 days.
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
Implied volatility for ANI Pharmaceuticals (ANIP) stock options is surging, particularly for the Apr 17, 2026 $55.00 Call. This indicates that the market anticipates a significant price movement for the stock, possibly due to an upcoming event. Despite this, analysts currently rate ANI Pharmaceuticals as a Zacks Rank #2 (Buy), with a slight upward revision in the Zacks Consensus Estimate for the current quarter.
40 Under 40: Kevin Chan, ANI Pharmaceuticals
Kevin Chan, currently Senior Director and Head of Ophthalmology Marketing at ANI Pharmaceuticals, is recognized in the "40 Under 40" list for his significant contributions to the pharmaceutical industry. With a background including a PharmD and early commercial digital strategy at Novartis Oncology, he played key roles in launching successful therapies like Arikayce and Izervay. Chan is celebrated for building his career from the ground up, driven by clinical training, curiosity, and collaboration.
ANI Pharmaceuticals (ANIP) Is Up 11.2% After Raising 2026 Revenue Outlook And Rare Disease Hiring Plan – Has The Bull Case Changed?
ANI Pharmaceuticals (ANIP) announced a raised 2026 revenue guidance, projecting $1.055 billion to $1.115 billion, and plans to hire approximately 90 more personnel for its Rare Disease division to boost Cortrophin Gel's growth. This strategic shift towards high-value specialty treatments like Cortrophin Gel is seen as central to the company's future revenue mix, with strong 2025 growth for the product further emphasized. The company's investment narrative now heavily relies on the successful execution of these Rare Disease plans, especially regarding Cortrophin Gel, amidst varying fair value estimates from analysts.
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
ANI Pharmaceuticals (ANIP) has reportedly returned 8% year-to-date, outperforming the Medical group's average gain of 7.1%. The stock holds a Zacks Rank of #2 (Buy) with improving analyst sentiment. However, ANIP slightly underperforms its specific industry, Medical - Biomedical and Genetics, which has gained 18.6% in the same period.
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 500 Shares of Stock
ANI Pharmaceuticals VP, Meredith Cook, sold 500 shares of company stock on January 13th for $42,165, reducing her ownership by 0.67%. The sale occurred at an average price of $84.33 per share. The company's stock currently trades around $85.03, and it recently beat Q3 earnings estimates with revenue up 53.6% year-over-year.
Ani Pharmaceuticals’ Cook sells $42,165 in stock
Meredith Cook, SR. VP, General Counsel & Sec. of ANI Pharmaceuticals Inc (NASDAQ:ANIP), sold 500 shares of common stock for a total of $42,165. This transaction, executed under a Rule 10b5-1 trading plan, leaves Cook with 74,374 directly owned shares. The company recently reported Q3 2025 earnings exceeding expectations and provided strong financial guidance for 2025, anticipating revenue surpassing $1 billion in 2026.
SG Americas Securities LLC Boosts Stock Position in ANI Pharmaceuticals, Inc. $ANIP
SG Americas Securities LLC significantly increased its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 791.1%, now holding 22,847 shares valued at $2.09 million. This move is part of a broader trend of institutional investors boosting their positions in the specialty pharmaceutical company. Despite recent insider selling, analysts maintain a "Moderate Buy" rating for ANIP, with an average price target of $102.14, and expect the company to post 3.86 EPS for the current fiscal year.
ANI Pharmaceuticals (ANIP) Is Up 7.0% After Raising 2026 Revenue Outlook and Expanding Rare Disease Team
ANI Pharmaceuticals (ANIP) saw its stock rise 7.0% after raising its 2026 revenue guidance to US$1.06 billion to US$1.12 billion, largely driven by its rare disease portfolio, particularly Purified Cortrophin Gel. The company also announced plans to hire approximately 90 additional rare disease specialists to expand the market for Cortrophin Gel. This strategic focus on its rare disease therapy is expected to be a core growth engine, though investors are cautioned about potential risks related to increased operating expenses and payer scrutiny.
Insider Sell Alert: Meredith Cook Sells Shares of ANI Pharmaceuticals Inc (ANIP)
Meredith Cook, Senior Vice President at ANI Pharmaceuticals Inc (ANIP), sold 500 shares of the company on January 13, 2026, reducing her holdings to 74,374 shares. This transaction is part of a pattern of insider selling at ANIP, with 39 insider sells and no insider buys in the past year. The stock is currently trading at $84.33 and is considered fairly valued based on its GF Value of $91.02.
Ani Pharmaceuticals’ Cook sells $42,165 in stock
Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals Inc, sold 500 shares of common stock for $42,165 on January 13, 2026, under a Rule 10b5-1 trading plan. The company shows strong financial health with nearly 49% revenue growth and exceeded third-quarter earnings expectations. ANI Pharmaceuticals anticipates significant financial growth, projecting over $1 billion in revenue for 2026, alongside strategic advancements in its ophthalmology and retina franchise.
ANI Pharmaceuticals Targets $1B+ 2026 Revenue as Rare Disease Pivot Accelerates, Cortrophin Leads Growth
ANI Pharmaceuticals is projecting over $1 billion in revenue for 2026, driven by an accelerating pivot towards rare disease medicines, with Purified Cortrophin Gel leading this growth. The company anticipates rare disease products will account for approximately 60% of its 2026 revenue. While the generics business will remain flat, it will continue to be a cash engine, enabling ANI to pursue future rare-disease focused mergers and acquisitions.
Stocks making big moves yesterday: OneMain, Nextpower, ANI Pharmaceuticals, Akamai Technologies, and Lemonade
This article highlights several stocks that experienced significant movement on Monday. OneMain (OMF) declined after a downgrade, while Nextpower (NXT) rose due to a new joint venture. ANI Pharmaceuticals (ANIP), Akamai Technologies (AKAM), and Lemonade (LMND) all saw gains following strong financial guidance, analyst upgrades, and new coverage, respectively.
ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why
Shares of ANI Pharmaceuticals (ANIP) fell 3.3% after investors took profits following strong preliminary 2025 results and an upbeat financial forecast for 2026. The company had previously projected 2026 net revenues between $1.055 billion and $1.115 billion, driven by the rare disease treatment Cortrophin Gel, leading to a 10% rally in the prior session. Despite the recent drop, the stock is up 2.8% year-to-date and offers a significant return to long-term investors.
ANI Pharmaceuticals expects over $1 billion in 2026 revenue By Investing.com
ANI Pharmaceuticals (NASDAQ:ANIP) announced that it expects to exceed its 2025 financial guidance and projects significant growth for 2026, targeting over $1 billion in total net revenues. The company's rare disease portfolio, particularly Cortrophin Gel, is a key driver of this growth. InvestingPro data indicates that ANI Pharmaceuticals appears undervalued, with analysts maintaining a strong buy consensus and a "GREAT" financial health score.
Decker Retirement Planning Inc. Boosts Position in ANI Pharmaceuticals, Inc. $ANIP
Decker Retirement Planning Inc. significantly increased its stake in ANI Pharmaceuticals (NASDAQ:ANIP) by 76,862.5% in the third quarter, now holding 36,942 shares valued at $3.38 million. This makes ANI Pharmaceuticals the 15th largest position in Decker's portfolio. Institutional investors collectively own 76.05% of the company, while recent insider sales amounted to 27,601 shares worth $2.41 million, with insiders still owning 12.70% of the stock.
Why ANI Pharmaceuticals (ANIP) Stock Is Trading Up Today
Shares of specialty pharmaceutical company ANI Pharmaceuticals (ANIP) jumped 13.6% after providing strong 2026 financial guidance that exceeded analyst expectations, projecting total net revenues between $1.055 billion and $1.115 billion. This growth is primarily driven by its rare disease treatment, Cortrophin Gel, with anticipated revenues of $540 million to $575 million. The company also reported strong preliminary 2025 results for the drug and plans to expand its rare disease team to support continued momentum.
ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2025 Earnings Guidance
ANI Pharmaceuticals (NASDAQ:ANIP) has updated its FY 2025 earnings guidance, projecting EPS between $7.37 and $7.64, exceeding the consensus estimate of $6.97. The company set revenue guidance for the same period at $854.0 million to $873.0 million, which aligns closely with the consensus of $869.3 million. This update follows a strong previous quarter where ANI Pharmaceuticals surpassed EPS and revenue expectations, and analysts currently maintain a "Moderate Buy" rating for the stock.
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
ANI Pharmaceuticals has announced exceptional growth for 2025, driven significantly by its Rare Disease business, especially Purified Cortrophin® Gel. The company projects over $1 billion in total net revenues for 2026, with the Rare Disease segment expected to contribute around 60%. Strategic priorities for 2026 include expanding its Rare Disease organization to target acute gouty arthritis flares and investing in R&D to support continued growth across its Generics and Brands businesses.
ANI Pharmaceuticals, Inc. CEO Nikhil Lalwani to Present at 44th Annual J.P. Morgan Healthcare Conference
ANI Pharmaceuticals, Inc. CEO Nikhil Lalwani is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will be webcast live and archived on the company's investor relations website for 30 days. This event aims to enhance the company's visibility and communicate its strategies for sustainable growth in rare diseases, generics, and brand products.
ANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 6.3% - Time to Sell?
ANI Pharmaceuticals (NASDAQ:ANIP) shares dropped 6.3% during Friday's mid-day trading on Friday, with volumes significantly lower than average. Despite the recent dip, analysts hold a "Moderate Buy" consensus rating with an average target price of $102.14. Insider selling has been observed, but institutional investors have largely increased their stakes in the company.
Do Strong 2025 Rare Disease Results Reshape the Bull Case for ANI Pharmaceuticals (ANIP)?
ANI Pharmaceuticals' CEO Nikhil Lalwani is set to present at the J.P. Morgan Healthcare Conference, drawing attention to the company's strong 2025 rare disease portfolio performance, including Cortrophin Gel and ophthalmology products. The company recently raised its 2025 revenue guidance to between US$854 million and US$873 million, largely due to this momentum. Investors will be evaluating the sustainability of the rare disease segment's contribution and considering potential payer pressure on ACTH growth.
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced that its CEO, Nikhil Lalwani, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will be available via a live and archived webcast on the company's website. ANI Pharmaceuticals is a diversified biopharmaceutical company focused on rare diseases, generics, and brands.
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced that its CEO, Nikhil Lalwani, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will be available via live and archived webcast on the company's website. ANI Pharmaceuticals is a biopharmaceutical company focusing on Rare Disease, Generics, and Brands businesses.
ANI Pharmaceuticals, Inc. CEO Nikhil Lalwani to Present at 44th Annual J.P. Morgan Healthcare Conference
ANI Pharmaceuticals, Inc. announced that CEO Nikhil Lalwani will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will be available via live and archived webcast, enhancing the company's visibility and demonstrating its commitment to communicating with investors. ANI Pharmaceuticals focuses on sustainable growth across its Rare Disease, Generics, and Brands businesses.
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced that its CEO, Nikhil Lalwani, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will be available via live and archived webcast on the company's investor relations website for 30 days. ANI Pharmaceuticals is a biopharmaceutical company specializing in rare disease, generics, and branded therapeutics.
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced that its CEO, Nikhil Lalwani, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET. A live and archived webcast of the presentation will be available on the company's website. ANI Pharmaceuticals is a diversified biopharmaceutical company focused on rare diseases, generics, and brands.
3 Reasons to Avoid ANIP and 1 Stock to Buy Instead
Despite ANI Pharmaceuticals (ANIP) outperforming the S&P 500 significantly over the past five years, the article advises caution. It highlights three reasons to avoid the stock: limited distribution channels affecting its market ceiling, a shrinking adjusted operating margin, and negative returns on invested capital from past growth initiatives. The article suggests that while ANIP's valuation is fair, the upside potential is unimpressive compared to potential downsides, and recommends other high-quality stocks instead.
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away
Stonepine Capital Management fully exited its position in ANI Pharmaceuticals, selling all 38,597 shares valued at $2.52 million. Despite this, ANI Pharmaceuticals' stock has surged 49% over the past year, outperforming the S&P 500, with Q3 revenue jumping 54% year-over-year. The exit appears to be a capital rotation strategy by Stonepine towards earlier-stage biotechs rather than a vote of no confidence in ANI's strong fundamentals.
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away
Oregon-based Stonepine Capital Management sold its entire position in ANI Pharmaceuticals (NASDAQ:ANIP) during the third quarter, totaling 38,597 shares worth $2.52 million. This full exit occurred despite ANI Pharmaceuticals stock being up 49% over the past year with surging revenue and strong third-quarter results. The fund's decision appears to be a capital rotation towards earlier-stage biotech, rather than a vote of no confidence in ANI's fundamentals.
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC reduced its stake in ANI Pharmaceuticals (ANIP) by 41.6% in Q3 2025, selling 22,482 shares and retaining 31,497 shares valued at $2.89 million. Insiders sold 28,001 shares totaling $2.45 million over the last 90 days, while institutions own 76.05% of the stock. ANI Pharmaceuticals exceeded Q3 EPS estimates with $2.04 and saw revenue increase by 53.6% year-over-year, leading to a "Moderate Buy" consensus rating among analysts with an average price target of $102.14.
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away
Stonepine Capital Management fully divested its 38,597 shares of ANI Pharmaceuticals, valued at $2.52 million, despite ANI's stock surging 49% over the past year and outperforming the S&P 500. This move is interpreted as a capital rotation by Stonepine towards earlier-stage biotech, rather than a vote of no confidence in ANI. ANI Pharmaceuticals itself has reported a 54% year-over-year revenue increase in its third quarter and strong adjusted EBITDA growth, driven by rare disease therapies.
ANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 3.6% on Insider Selling
ANI Pharmaceuticals (NASDAQ:ANIP) experienced a 3.6% mid-day drop following insider selling, specifically by SVP Krista Davis who sold 1,622 shares. Despite this, analyst sentiment remains generally positive, with a "Moderate Buy" rating and an average price target of $102.14. The company also reported strong Q3 earnings, beating expectations with $2.04 EPS and a 53.6% year-over-year revenue increase.
